08 January 2026   While the human central nervous system (CNS) has often been modelled with organoids, progress in constructing the peripheral nervous system (PNS) has been relatively limited. Yet, the PNS plays a crucial role in communication between different areas of the body and the brain and dysfunction in PNS has been tied to a number of chronic diseases.   The PNS has two main subsystems, one of which is the autonomic nervous system, which automatically controls physio

26 September 2025   Hepatotoxicity, including drug-induced liver injury (DILI), is a leading cause of patient attrition, drug development discontinuation  and post-marketing withdrawal , resulting in significant morbidity and mortality. Conversely to direct DILI, idiosyncratic DILI (iDILI) is caused by drugs with little or no intrinsic hepatotoxicity, is not dose-dependent, and occurs with a longer latency period. The majority of DILI cases encountered in the clinical setting

08 July 2025   Despite extensive biomedical research, disease-modifying treatments for human neurodevelopmental disorders such as autism spectrum disorder and schizophrenia are still lacking. Neurology and psychiatry are consistently the lowest success categories in drug development, with a 95-97% failure rate in clinical trials. Owing to inter-species differences in brain anatomy and physiology, animal models do not recapitulate human-specific molecular and cellular pathways

02 October 2025   Microvessels - capillaries and post‑capillary venules - are the smallest vessels in the circulation, with a cellular composition and thin-walled structure that enables nutrient exchange, oxygen delivery, waste removal, and immune‑cell trafficking between the blood and surrounding tissue cells. The absence of microvascular function is often cited as a major bottleneck of in vitro preclinical models, leading to tissue necrosis and limiting physiological releva

10 February 2026   European pioneers of human-based microphysiological systems (MPS) announce  the launch of of IAMPS – the Industry Alliance for Microphysiological Systems, dedicated to advancing MPS technologies. This alliance was formed by leading innovators in next gen human biology platforms  – AlveoliX (Switzerland), BiomimX (Italy), chiron (Netherlands), Dynamic42 (Germany), InSphero (Switzerland), MIMETAS (Netherlands), NETRI (France), React4Life (Italy), and TissUse

24 September 2025   Berkeley-based Prellis Biologics, Inc. , developer of human in vitro antibody generation platform, announces collaboration with Eli Lilly to accelerate the discovery of human antibodies for multiple disease targets.   Prellis’ EXIS™ lymph node platform for target‑specific human antibody generation is a shining example of ingenuity by which several technologies were combined to capture human-relevant physiology.   The traditional method of antibody generat

23 September 2025   Vienna-based Heartbeat.bio , developer of breakthrough therapies for cardiac disorders through its proprietary human-based in vitro cardioid drug discovery platform, announces  it has entered into a research collaboration with Boehringer Ingelheim to develop gene therapy-based treatments for genetic cardiomyopathies.   Genetic cardiac pathologies such as hypertrophic, dilated, arrhythmogenic right ventricular and restrictive cardiomyopathy, are typically c

25 September 2025   Cedars-Sinai Medical Center based in Los Angeles has been awarded $5M by Advanced Research Projects Agency for Health (ARPA-H) to develop a human-based AI-driven KronosRx platform  for improved prediction of adverse drug effects.   The ARPA-H Computational ADME-Tox and Physiology Analysis for Safer Therapeutics ( CATALYST ) program aims to revolutionize preclinical drug safety prediction by facilitating the development of next gen in vitro and in silico mo

12 June 2025   Cambridge, Massachusetts-based Parallel Bio announces  it has raised $21 million Series A funding to scale up and automate the production of its immune organoid in vitro platform. This funding round led by AIX Ventures was supported by prominent leaders in AI and biotech, including Marc Benioff, founder and CEO of Salesforce.   Beyond infections and autoimmune diseases, it is widely recognized that the human immune systems plays a key role in a great number of

31 January 2026   Mahzi Therapeutics-sponsored Phase 1/2 study  to assess safety and efficacy of MZ-1866 gene therapy for children and adults with Pitt Hopkins syndrome is about to start. The trial was announced  by Mahzi in 2025, highlighting the sponsor's collaboration with the Pitt Hopkins Research Foundation and the Muotri Lab at UC San Diego in developing this long awaited treatment.   Pitt-Hopkins syndrome is a rare genetic disorder caused by mutations in the transcript

27 October 2025   As we enter a new era of drug discovery, where IND authorization can now be granted based on human data only, marking a clean departure from mandatory animal testing, Qureator's human organ-on-chip platform has laid the groundwork for the world’s first IND approval of its kind .   The IND grant concerns SillaJen's BAL0891-tislelizumab combination therapy to treat solid tumors. Qureator's patient-derived vascularized tumor immune microenvironment (TME) model

26 September 2025   Inductive Bio , an AI drug discovery partner developing virtual chemistry labs, is awarded up to $21M by Advanced Research Projects Agency for Health (ARPA-H)  to develop AI-powered human-relevant drug toxicity prediction models. ARPA-H Computational ADME-Tox and Physiology Analysis for Safer Therapeutics  (CATALYST) program aims to revolutionize preclinical drug safety prediction by leveraging human-based models that assess safety of drug candidates more